摘要
目的:研究百令疏肝胶囊对二甲基亚硝胺诱导的大鼠肝纤维化的作用。方法:用二甲基亚硝胺诱导肝纤维化模型。酶联免疫法测定血清Ⅲ型前胶原肽、层粘连蛋白、基质金属蛋白酶抑制因子1的浓度,化学比色法测定血清白蛋白的浓度和肝组织羟脯氨酸的含量。使用Motic Med6.0数码医学图像分析系统测量肝纤维化面积。结果:百令疏肝胶囊高(450 mg·kg-1)、中(270mg·kg-1)和低(90 mg·kg-1)剂量组的血清Ⅲ型前胶原肽水平[分别为(34.46±13.95)、(36.15±9.46)和(40.58±7.72)ng·ml-1]、基质金属蛋白酶抑制因子1水平[分别为(16.65±4.24)、(16.66±4.34)和(18.99±6.05)ng·ml-1]、层粘连蛋白水平[分别为(12.94±4.29)、(12.96±3.21)和(15.32±8.00)ng·ml-1]和肝组织纤维化面积[分别为(0.02240±0.01337)、(0.02176±0.01460)和(0.02384±0.01405)μm2]显著低于模型组的相应值[(49.38±10.95)ng·ml-1、(30.84±14.48)ng·ml-1、(30.22±17.00)ng·ml-1、(0.03929±0.01732)μm2];高、中剂量组的肝组织中羟脯氨酸水平分别为(0.77±0.09)、(0.81±0.09)μg·mg湿重-1,显著低于模型组的(1.06±0.33)μg·mg湿重-1;高剂量组的肝组织中白蛋白水平为(34.02±4.17)g·L-1,显著高于模型组的(30.25±4.21)g·L-1。结论:百令疏肝胶囊对二甲基亚硝胺诱导的大鼠肝纤维化具有治疗作用。
Objective:To investigate the effects of Corbrin Shugan capsule on dimethylnitrosamine (DMN)-induced hepatic fibrosis in rats.Methods:Hepatic fibrosis was induced by DMN in AD rats.The serum concentrations of Ⅲ pro-collagen (Ⅲ PC),laminin (LN) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were determined with ELISA.The concentration of albumin (ALB) in sera and the content of hydroxyproline (Hyp) in liver tissues were determined with chemical colorimetric and HPLC,respectively.The fibrosis area was measured with Motic Med 6.0 digital medical image analysis system.Results:Compared to model group the high-dose (450 mg · kg^-1),mid-dose (270 mg · kg^-1)and low-dose (90 mg· kg^-1) groups of Corbrin Shugan capsule had significantly lower serum content of Ⅲ PC [(34.46±13.95),(36.15 ±9.46),and (40.58 ±7.72)ng · ml^-1 vs (49.38 ± 10.95)ng ·ml^-1,P 〈0.05 orP〈0.01],TIMP-1 [(16.65 ±4.24),(16.66 ±4.34),and (18.99 ±6.05)ng·ml^-1 vs (30.84 ± 14.48)ng · ml^-1,P 〈0.05 or P 〈0.01],LN [(12.94 ±4.29),(12.96 ±3.21),and (15.32 ± 8.00) ng · ml^-1 vs (30.22 ± 17.00) ng · ml^-1,P 〈 0.05 or P 〈 0.01] and smaller hepatic fibrosis area [(0.02240 ± 0.01337),(0.02176 ± 0.01460) and (0.02384 ± 0.01405) μm2 vs (0.03929 ± 0.01732) μm2,P 〈 0.05 or P 〈 0.01] ; the high-dose and mid-dose groups of Corbrin Shugan capsule had significantly lower content of Hyp in liver tissues [(0.77 ± 0.09) and (0.81 ±0.09) μg · mg^-1 vs (1.06 ± 0.33) μg · mg^-1,P 〈 0.05 or P 〈 0.01] ; and the high-dose group of Corbrin Shugan capsule significantly increased the content of ALB in sera [(34.02 ± 4.17)g · L-1 vs (30.25 ± 4.21) g · L-1,P 〈 0.05].Conclusion:Corbrin Shugan capsule is effective in treatment of DMN-indueed hepatic fibrosis in rats.
出处
《浙江大学学报(医学版)》
CAS
CSCD
北大核心
2013年第5期561-566,共6页
Journal of Zhejiang University(Medical Sciences)
基金
浙江省科技计划(2011C23100)